KTKarina Hammer Tømmerdal

Karina Hammer Tømmerdal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karina Hammer Tømmerdal has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High-intensity progressive resistance training to prevent falls in community-dwelling adults aged 80 years and older with reduced muscle strength: protocol for the ReFit randomised controlled trial

    by Jonathan Berg, Karina Hammer Tømmerdal, Jeff S. Coombes, Turid Follestad, Øyvind O. Salvesen, Erik Madssen, Geir Selbæk, Håvard Dalen, Gudrun M. W. Bjørnelv, Brooke L. Devlin, et al.

    Introduction: Falls are a major cause of injury-related morbidity, mortality, and healthcare utilisation among older adults, with the greatest burden occurring in those aged ≥80 years. Multicomponent exercise programmes that include balance and resistance exercises reduce falls, whereas the effect of resistance training delivered as a standalone fall-prevention intervention remains uncertain. Existing resistance-training trials have generally been small, underpowered for fall outcomes, and have produced inconsistent findings, despite reduced muscle strength being an important modifiable risk factor in the oldest old. The resistance training prescription used in these studies has not always aligned with recommendations for optimal strength adaptations in terms of intensity or progressive overload, which may explain this uncertain efficacy. Therefore, this study aims to determine whether 12 months of high-intensity progressive resistance training reduces fall rates in community-dwelling adults aged ≥80 years with reduced muscle strength. Methods and analysis: This single-centre, randomised controlled trial conducted in Trondheim, Norway, includes 241 community-dwelling adults aged ≥80 years with reduced muscle strength. Participants are randomly assigned (1:1) to either standard care with written physical activity guidance or a twice-weekly high-intensity progressive resistance training intervention for 12 months. The primary outcome is the rate of falls over 12 months. Secondary outcomes include time to first fall, fall-related injuries, muscular function, physical performance, balance, body composition, cardiometabolic health, cognition, and participant-reported outcomes. Cost-effectiveness is assessed from a healthcare perspective over the 12-month intervention period using costs and quality-adjusted life years. Analyses follow the intention-to-treat principle, using negative binomial regression for the primary outcome. The first participant was included on 30 March 2023, and the last participant was included on 29 September 2025. The 12-month intervention period is expected to be completed by September 2026. Ethics and dissemination: The study has received approval from the Regional Committee for Medical and Health Research Ethics in Norway (REK; reference number 462261). All participants provided written informed consent before participating. Findings will be shared via peer-reviewed publications, conference presentations, and communication with stakeholders and the public. Trial registration number: ClinicalTrials.gov ( NCT05691166 ), registered 11 January 2023. Available at: https://clinicaltrials.gov/study/NCT05691166

  • Open Access

    Physical activity patterns from mid- to late adulthood and risk of sarcopenia in older adults: the HUNT study

    by Karina Hammer Tømmerdal, Javaid Nauman, Erik Madssen, Jari Antero Laukkanen, Arnt Erik Tjønna, Ulrik Wisløff, Jonathan Berg

    Background: While cross-sectional studies suggest that physical activity (PA) is associated with a lower risk of sarcopenia, the long-term PA patterns remain poorly characterized. We aimed to examine whether PA patterns across mid- to late adulthood are associated with sarcopenia in older age. Methods: We included 4702 individuals (mean age 76.4 ± 5.0 years, 53% female) from the HUNT4 (Trøndelag Health Study) 70+ cohort with PA data across three prior waves (HUNT1–3). PA was categorized as active or inactive at each time point (1984-86, 1995-97, 2006-08) according to the World Health Organization 2020 guidelines. Sarcopenia at HUNT4 (2017-19) was defined according to the European Working Group on Sarcopenia (EWGSOP2) criteria as probable (low strength) or confirmed (low strength and low muscle mass). Logistic regression analyses were used to examine associations between long-term PA patterns and sarcopenia. Results: PA showed a clear inverse dose-response relationship with sarcopenia, with stronger associations for confirmed than probable sarcopenia. Compared with persistent inactivity, being active at all three time points was associated with 78% lower odds of confirmed sarcopenia at HUNT4 (OR 0.22, 95% CI: 0.08-0.66). Participants active at two and one time points had 40% (OR 0.60, 0.38-0.95) and 26% (OR 0.74, 0.55-1.00) lower odds, respectively. Associations varied by PA pattern, with lower odds observed among those becoming active (OR 0.57, 0.39–0.84) but not among those becoming inactive. Conclusion: Long-term PA shows a clear dose–response relationship with sarcopenia risk in later life. While sustained activity across adulthood confers the greatest benefit, initiating PA even later in life remains associated with lower odds of sarcopenia.